Anti-SARS-CoV-2 spike receptor binding domain (S-RBD) IgG antibodies following CoronaVac administration: a longitudinal study. Anti-SARS-CoV-2 S-RBD IgG antibodies

Reports on antibody titers following CoronaVac administration are still scarce, particularly when it comes to the post-vaccination effectiveness of CoronaVac in the Indonesian population. The purpose of  this study is to determine the efficacy of COVID-19 vaccination by comparing the IgG levels against the S1 subunit of SARS-CoV-2 RBD after the first and second vaccinations. The researchers collected venous blood samples from participants after they received the CoronaVac 600 SU/0.5 mL vaccine at two different intervals (14 days and 28 days). Blood was drawn twice (after the first and second vaccinations) and tested for antibodies (positive antibody detection value of 50 AU/mL). Paired data were analyzed by using either the Wilcoxon test (numerical) or the McNemar test (categorical). The median IgG1 levels in the 14-day interval between vaccine doses were 64.40 AU/mL and IgG2 levels were 886.10 AU/mL. Meanwhile, the median IgG1 level was 146.10, and IgG2 level was 688.00.AU/mL in the group with a 28-day interval between vaccine doses. After the first vaccination, 60.00 % of study subjects had positive IgG levels, which increased to 98.57% after the second vaccination. Following the full-dose vaccination, all participants had higher antibody levels, and considered significant. The effect was stronger in the group that received the vaccine at 14-day intervals. CoronaVac has also been shown to increase the prevalence of detectable antibody positivity in study participants.

1. Speiser DE, Bachmann MF. Covid-19: Mechanisms of vaccination and immunity. Vaccines, 2020, Vol. 8, no. 3, pp. 404.

2. Min L, Sun Q Antibodies and Vaccines Target RBD of SARS-CoV-2. Front Mol Biosci, 2021, Vol. 8, pp. 247.

3. Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines, 2021, Vol . 6, no. 1, pp. 1–17.

4. Rego GNA, Nucci MP, Alves AH, Oliveira FA, Marti LC, Nucci LP, et al. Current clinical trials protocols and the global effort for immunization against sars-cov-2. Vaccines, 2020, Vol. 8, no. 3, pp. 474.

5.

6. Calina D, Docea AO, Petrakis D, Egorov AM, Ishmukhametov AA, Gabibov AG, et al. Towards effective COVID‑19 vaccines: Updates, perspectives and challenges. Int J Mol Med, 2020, Vol. 46, no. 1, pp. 3–16.

7. Krause PR, Gruber MF. Emergency use authorization of Covid vaccines—safety and efficacy follow-up considerations. N Engl J Med, 2020, Vol. 383, no. 19, pp. e107.

8. Munro C. Covid-19: 40% of patients with weakened immune system mount lower response to vaccines. BMJ. 2021, Vol. 374, pp. n2098.

9. Nugraha RR, Miranda AV, Ahmadi A, Lucero-Prisno DE. Accelerating Indonesian COVID-19 vaccination rollout: a critical task amid the second wave. Trop Med Health, 2021, Vol. 49, no. 1, pp. 76.

10. Wilder-Smith A, Mulholland K. Effectiveness of an Inactivated SARS-CoV-2 Vaccine. N Engl J Med, 2021, Vol. 385, pp. 946–8.

11. Cabinet Secretariat of the Republic of Indonesia. (2021) BPOM Allows Use of Sinovac Vaccine for Children Aged 6-11. [Cited 8 December 2021]. Available from: https://setkab.go.id/en/bpom-allows-use-of-sinovac-vaccine-for-children-aged-6-11/.

12. Ganji KS, Mohammadzadeh I, Mohammadnia-Afrouzi M, Ebrahimpour S, Shahbazi M. Factors affecting immune responses to vaccines. Gazz Medica Ital Arch per le Sci Mediche, 2018, Vol. 177, no. 5, pp. 219–28.

13. Melgoza-González EA, Hinojosa-Trujillo D, Reséndiz-Sandoval M, Mata-Haro V, Hernández-Valenzuela S, García-Vega M, Bravo-Parra M, Arvizu-Flores AA, Valenzuela O, Velázquez E, Soto-Gaxiola A, Gómez-Meza MB, Pérez-Jacobo F, Villela L, Hernández J. Analysis of IgG, IgA and IgM antibodies against SARS-CoV-2 spike protein S1 in convalescent and vaccinated patients with the Pfizer-BioNTech and CanSinoBio vaccines. Transbound Emerg Dis, 2021, pp. 1-12. Doi: 10.1111/tbed.14344.

14. Ulhaq ZS, Soraya GV, Indriana K, Devitasari R, Pradiptha IPY, Zulfikar DB, Uxiana V, Zulkarnain, Rachma LN, Arisanti D. The level of Ig anti-RBD SARS-CoV-2 after two doses of CoronaVac vaccine. J Med Virol, 2022, Vol. 94, pp. 829-32.

15. Bayram A, Demirbakan H, Karadeniz PG, Erdoğan M, Koçer I. Quantitation of antibodies against SARS‐CoV‐2 spike protein after two doses of CoronaVac in health care workers. J Med Virol, 2021, Vol. 93, no. 9, pp. 5560–5567.

16. Akpolat T, Uzun O. Reduced mortality rate after coronavac vaccine among healthcare workers. J Infect, 2021, Vol. 83, no. 2, pp. e20–1.

17. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med, 2021, Vol. 385, no. 10, pp. 875–84.

18. Binay UD, Karakecili F, Binali E, Barkay O, Gul O, Mertoglu C. Level of SARS-CoV-2 IgG antibodies after two doses CoronaVac vaccine: Primarily report. J Antivir Antiretrovir, 2021, Vol. 13, no. S18, pp. 005.

19. Lippi G, Henry BM, Plebani M. Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How? Diagnostics, 2021, Vol. 11, no. 6, pp. 941.

20. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 2021, Vol. 21, no. 2, pp. 181–92.

21. Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet, 2021, Vol. 398, no. 10296, pp. 213–22.

22. Ranzani OT, Hitchings MDT, Dorion M, D’Agostini TL, de Paula RC, de Paula OFP, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ, 2021, Vol. 374, pp. n2015.

23. Keskin AU, Bolukcu S, Ciragil P, Topkaya AE. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. J Med Virol, 2022, Vol. 94, no. 1, pp. 39-41.